The Percutaneous Absorption-Type Analgesic and Anti-inflammatory Drug
Loxonin® Tape 50mg/100mg
Receives Approval for Manufacture and Marketing

Tokyo, March 12, 2008 – DAIICHI SANKYO COMPANY, LIMITED (President and representative director: Takashi Shoda) and Lead Chemical Co., Ltd. (President: Masao Mori) today announced that they received an approval for manufacture and marketing of the percutaneous absorption-type analgesic and anti-inflammatory preparation, Loxonin® Tape 50mg/100mg (generic name: loxoprofen sodium) by the Japanese Ministry of Health, Labour and Welfare on March 7, 2008. The product is jointly developed by both firms.

Loxonin® Tape is the first loxoprofen sodium adhesive tape in Japan containing the same constituents as Loxonin® pills and Loxonin® powder which are leading agents among orally administered analgesic and anti-inflammatory drugs. The adhesive tape is expected to have superior analgesic and anti-inflammatory efficacy when applied once per day.

Following the launch of Loxonin® Pap in 2006, we are confident that this new addition to the long-standing top brand Loxonin® will further contribute to analgesic and anti-inflammatory drug treatment.

This preparation is scheduled to be manufactured by Lead Chemical and sold by DAIICHI SANKYO.

For further information, please contact:

DAIICHI SANKYO COMPANY, LIMITED
Corporate Communications Department
3-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo 103-8426, Japan
Tel: +81-3-6225-1126

Lead Chemical Co., Ltd.
77-3 Himata, Toyama City, Toyama 930-0912, Japan